SAN FRANCISCO — For any hopes the dealmaking ... A biotech stock index slid by almost 3%. Amgen is one of those would-be competitors and, at the JPM meeting, executives defended recent trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback